A case of cephalothin-associated urolithiasis by Lim, Ivan WM et al.
© 2011 Lim et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Pharmacology: Advances and Applications 2011:3 1–3
Clinical Pharmacology: Advances and Applications Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
CAse rePOrT
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CPAA.S16516
A case of cephalothin-associated urolithiasis
Ivan WM Lim1
Peter JO stride1,2
robert L Horvath3
1Department of Medicine, redcliffe 
Hospital, redcliffe, Queensland, 
Australia; 2University of Queensland 
school of Medicine, redcliffe, 
Queensland, Australia; 3Infectious 
Diseases Department, Prince Charles 
Hospital, Brisbane, Queensland, 
Australia
Correspondence: Peter JO stride 
Department of Medicine, redcliffe 
Hospital, University of Queensland school 
of Medicine, Anzac Avenue, redcliffe, 
Queensland, Australia 4020 
Tel +61 04 17039111/+61 04 38837777 
Fax +61 04 38837214 
email peter_stride@health.qld.gov.au
Abstract: We present a case of osteomyelitis requiring prolonged intravenous cephalothin 
complicated by symptomatic calcium oxalate urocalculi formation. Patients on long-term 
β-lactam antibiotics with lower urinary tract symptoms may have urolithiasis rather than a 
urinary tract infection.
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Case report
A previously healthy 39-year-old male was admitted with right mid-tibial osteomyelitis, 
having sustained a 0.3-cm laceration in his right shin 2 months earlier from cut foliage 
while chopping pine trees. He neglected this lesion, did not seek medical advice, and 
developed an ulcer with surrounding cellulitis.
After 1 month, the lesion was ∼0.5 cm in diameter, but his general practitioner 
predicted healing without specific treatment. After 2 months, the lesion enlarged further 
with ulceration and necrosis necessitating hospital referral. The patient had no signifi-
cant past medical history and denied smoking, diabetes, recent travels, or any history 
suggestive of immunodeficiency.
On admission, computed tomography of the right tibia revealed a gas-containing 
soft-tissue defect eroding the anterior adjacent cortex of tibia compatible with a sub-
periosteal abscess with osteomyelitis (Figure 1).
The lesion was washed, debrided, and covered with a vacuum-assisted closure 
(VAC) dressing. He was treated empirically with intravenous cephalothin 1 g QID. 
Methicillin-sensitive Staphylococcus aureus (MSSA) was cultured from wound swabs. 
Six weeks of therapy was planned via a peripherally inserted central catheter line to 
expedite home therapy.
However, after 5 weeks of therapy, he developed intense dysuria, frank hematuria 
with the passage of clots, and intermittent fever up to 39.5°C, and then a widespread 
erythematous rash following commencement of gentamicin for a suspected urinary 
tract infection.
Investigations
Results of the diagnostic tests are shown in Table 1. Urinary tract symptoms per-
sisted during 6 days of therapy with gentamicin and continued cephalothin. His 
symptoms finally resolved slowly over the next 3 days, when gentamicin and 
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occurrence of sexually transmitted diseases in the past or 
any risky sexual behaviors and also said he had never suf-
fered from urinary tract infections or renal calculi. The 
alternative diagnoses of   cephalothin-tract infection were 
considered.
He then had a split skin graft over his improving wound 
site. Cephalothin was replaced with intravenous lincomycin 
for 2 days, and he was subsequently discharged with oral 
clindamycin.
At clinic review in 2 weeks, graft failure with an underlying 
infection necessitated admission and repeat debridement, 
washout, and VAC dressing. Intravenous   cephalothin was 
started empirically postoperatively, and within 24 hours, he 
developed lower urinary tract symptoms again. Urine micro-
scopy revealed white cell count .500, red cell count .500, 
no growth after 48-hour incubation, no casts, but presence 
of calcium oxalate crystals. The 24-h urine collection showed 
calcium 9.9 mmol/24 hours (reference range [RR]: 1.2–10.0) 
and phosphate 86.5 mmol/24 hours (RR: 11.0–32.0). 
Corrected serum calcium and phosphate were normal at 
2.36 mmol/hour (RR: 2.15–2.55) and 1.24 mmol/hour 
(RR: 0.81–1.45), respectively, with   epidermal growth factor 
receptor .90. Cephalothin was ceased and urinary symptoms 
resolved within 24 hours. Subsequently, Morganella morganii  
sensitive to cotrimoxazole and gentamicin.was cultured from 
an intra-operative bone specimen, expediting a therapy 
change to co-trimoxazole.
Discussion
Drugs may be responsible for 1%–2% of all renal calculi.1 
Although our patient had urinary calcium excretion at the 
upper limit of normal and long periods of bed rest, he only 
had nephrolithiasis while on intravenous cephalothin therapy, 
even though this was accompanied by an increased fluid 
intake from concurrent intravenous fluids. Drug-  induced 
urolithiasis has two possible pathophysiological   explanations. 
Firstly, poorly soluble drugs with high urinary excretion and 
concentration may precipitate as crystals. Secondly, follow-
ing high-dose prolonged treatment, metabolic drug effects, 
such as alteration of urine pH, glomerular filtration rate, 
tubular reabsorption, and tubular secretion of drugs, may 
induce urolithiasis.2 Cephalothin has not been associated 
with urolithiasis; however, its use outside Australia is 
less frequent, where ceftriaxone is the cephalosporin of 
choice. There have been case reports of ceftriaxone-induced 
  nephrolithiasis and biliary calculi.3,4 A prospective study of 
51 children showed a 7-day course of normal or high-dose 
ceftriaxone resulted in 7.8% of children developing 
asymptomatic renal stones.5 Mazhari and Kimmel suggested 
that all cephalosporins have the potential to induce 
urolithiasis.6
Summary
Physicians should be aware that patients on long-term cepha-
losporin have the potential to develop urinary calculi. They 
may well be the cause of lower urinary tract symptoms instead 
of a urinary tract infection and should be stopped.
Figure 1 Osteomyelitis of the right tibia.
Table 1 Diagnostic test results
Hemoglobin 143 g/L rr: 135–180
White cell count 3.4 × 109/L rr: 4.0–11.0
  Neutrophils 1.77 × 109/L rr: 2.0–8.0
  Lymphocytes 0.85 × 109/L rr: 1.0–4.0
C-reactive protein 42 n , 15
Hemolytic screen Negative
Blood urea serum  
electrolytes/creatinine/ 
liver function tests
Normal
Urine protein  
creatinine ratio
470/5
Midstream urine
red cell count 90 n , 10
White cell count 100 n , 10
epithelial cells ,10 n , 10
Culture Negative
Urethral swabs Negative
PCr gonorrhea Negative
PCr chlamydia Negative
Urine cytology Urothelial cells,  
eosinophils, 
no malignant cells
Wound swab Negative
Blood culture Negative
Chest X-ray Normal
renal ultrasound Normal
Abbreviations: rr, reference range; PCr, polymerase chain reaction.Clinical Pharmacology: Advances and Applications
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